Peptides and combination of peptides for use in immunotherapy against various tumors
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
1. An antibody that specifically binds to a peptide consisting of the amino acid sequence of VIFEGEPMYL (SEQ ID NO: 168) or a human major histocompatibility complex (MHC) complexed with the peptide.
2. The antibody according to claim 1 wherein the antibody is a polyclonal antibody, monoclonal antibody, bi-specific antibody or a chimeric antibody.
3. The antibody of claim 1 , wherein the MHC complexed with the peptide is present in a tumor cell.
4. The antibody of claim 3 , wherein the tumor cell is at least one selected from the group consisting of hepatocellular carcinoma (HCC), colorectal cancer (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia/prostate cancer (BPH/PCA), ovarian cancer (OC), Merkel cell carcinoma (MCC), melanoma (MEL), breast cancer (BRCA), small cell lung cancer (SCLC), non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML), gallbladder adenocarcinoma and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), uterine cancer (UEC), and chronic lymphocytic leukemia (CLL).
5. The antibody of claim 3 , wherein the tumor cell is at least one selected from the group consisting of NSCLC, BRCA, and NHL.
6. The antibody of claim 1 , wherein the antibody is labeled with a toxin.
7. The antibody of claim 1 , wherein the antibody is labeled with a radionucleotide.
8. The antibody of claim 7 , wherein the radionucleotide is 111 In, 99 Tc, 14 C, 131 I, 3 H, 32 P, or 35 S.
9. The antibody of claim 1 , wherein the affinity value (Kd) of the antibody is less than 1×10 μM.
10. The antibody of claim 1 , wherein the MHC is a MHC class I molecule.
11. The antibody of claim 1 , wherein the MHC is a MHC class II molecule.
12. The antibody of claim 1 , further comprising a binding affinity of below 20 nanomolar.
13. The antibody of claim 1 , wherein the antibody is humanized.
14. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
15. The composition of claim 14 , wherein the pharmaceutically acceptable carrier is saline, Ringer's solution, dextrose solution, and/or solid hydrophobic polymer.
16. The composition of claim 15 , wherein the solid hydrophobic polymer is film, liposome, or microparticle.
17. A pharmaceutical composition comprising the antibody of claim 3 and a pharmaceutically acceptable carrier.
18. A pharmaceutical composition comprising the antibody of claim 6 and a pharmaceutically acceptable carrier.
19. A pharmaceutical composition comprising the antibody of claim 7 and a pharmaceutically acceptable carrier.
20. A pharmaceutical composition comprising the antibody of claim 10 and a pharmaceutically acceptable carrier.